|
December 4, 2003
|
Telik Announces
Completion of $172.5 Million Common Stock Offering |
|
December 3, 2003
|
Telik Announces
Interim Phase 1-2a TELINTRA™ Clinical Data in Resistant
Myelodysplastic Syndrome to be Presented at American Society
of Hematology Meeting |
|
December 2, 2003
|
Telik Announces
FDA Fast Track Designation for TELCYTA™ for Non-Small Cell
Lung Cancer |
|
November 19, 2003
|
Telik's
TELINTRA™ Demonstrates Clinical Activity in Resistant Myelodysplastic
Syndrome in Phase 1-2a Trial |
|
November 19, 2003
|
Telik Announces
Interim Results Showing Clinical Efficacy with TELCYTA™
in Combination with DOCETAXEL in Phase 1-2a Clinical Trial in
Second and Third Line Non-Small Cell Lung Cancer Patients |
|
November 19, 2003
|
Telik Announces Positive Interim Results from Phase 1-2a
Clinical Trial of TELCYTA™ in Combination with DOXIL®
in Platinum Refractory or Resistant Ovarian Cancer
|
|
November 19, 2003
|
Telik's TELCYTA™ Demonstrates 63% Objective Response
Rate in Combination with CARBOPLATIN in Platinum Refractory
r Resistant Ovarian Cancer in Phase 1-2a Trial
|
|
November 13, 2003
|
Telik Announces
Presentations at AACR-NCI-EORTC Conference |
|
November 6, 2003
|
Telik Announces
Pricing of Equity Offering |
|
October 29, 2003
|
Telik Announces
Proposed Equity Offering |
| |
Top |
|
October 29, 2003
|
Telik Announces
Third Quarter 2003 Financial Results |
|
October 21, 2003
|
Telik Announces Positive Interim Results from Phase 1-2a
Clinical Trial of TELCYTA™ (TLK286) in Combination with
CARBOPLATIN
|
|
October 21, 2003
|
Telik Announces Positive Interim Results from Phase 1-2a
Trial of TELCYTA™ (TLK286) in Combination with DOCETAXEL
|
|
October 21, 2003
|
Telik Announces Positive Interim Results from Phase 1-2a
Trial of TELCYTA™ (TLK286) in Combination with DOXIL®
|
|
October 1, 2003
|
Telik Announces Successful Completion of FDA Special Protocol
Assessment Review for TELCYTA™
|
|
September 19, 2003
|
Telik Announces Webcast of Presentation at UBS Global Life
Sciences Conference
|
|
September 11, 2003
|
Telik Announces Election of Mary Ann Gray, Ph.D. to Board
of Directors
|
| September
5, 2003 |
Telik Announces Presentation at Bear Stearns Healthcare
Conference
|
| September
3, 2003 |
Telik Announces FDA Fast Track Designation for TELCYTA™
|
| August
28, 2003 |
Telik Announces Webcast of Presentation at Thomas Weisel
Partners Healthcare Tailwinds 2003 Conference
|
| |
Top |
| August
14, 2003 |
Telik Announces Positive Follow-Up Results from Phase 2
Trial of TELCYTA™ in Advanced Non-small Cell Lung Cancer
|
| July
30, 2003 |
Telik Announces Second Quarter 2003 Financial Results
|
| July
25, 2003 |
Telik Announces Conference Call and Webcast to Discuss Second
Quarter 2003 Financial Results and Provide Company Update
|
| June
24, 2003 |
Telik Announces Webcast of Presentation at Wachovia Securities
Nantucket Conference
|
| June
12, 2003 |
Telik Announces Webcast of Presentation at Thomas Weisel
Partners Growth Forum
|
| June
4, 2003 |
Telik Announces Webcast of Presentation Needham & Company
Biotechnology Conference
|
| June
2, 2003 |
Telik¹s TELCYTA™ (TLK286) Demonstrates Significant
Clinical Activity Advanced Metastatic Breast Cancer
|
| June
1, 2003 |
Telik Announces Confirmatory Results from Second Phase 2
Trial of TELCYTA™ (TLK286) in Advanced Ovarian Cancer
|
| June
1, 2003 |
Telik Announces Confirmatory Results from Second Phase Trial
of TELCYTA™ in Advance Non-Small Cell Lung Cancer
|
| May
28, 2003 |
Telik Announces TELCYTA™ Presentations at ASCO Meeting
|
| |
Top |
|
April 24, 2003 |
Telik Announces
First Quarter 2003 Financial Results |
|
April 18, 2003 |
Telik Announces
Quarterly Financial Release, Conference Call and Webcast |
|
April 10, 2003 |
Telik Announces
Drug Discovery Collaboration with Roche |
|
April 9, 2003 |
Telik's
Trap Drug Discovery Technology Used To Identify Several New
Small Molecule Cancer Drug Candidates |
|
April 9, 2003 |
Telik Announces
Positive Interim Results Demonstrating Clinical Activity of
TLK199 in Myelodysplastic Syndrome |
|
April 9, 2003 |
Telik Announces
New Preclinical Data on TLK286 That Supports Unique Mechanism
of Activation, and Activity in Combinations with Standard Cancer
Drugs |
|
April 2, 2003 |
Telik Announces
Additions to Board of Directors |
|
March 27, 2003 |
Telik Initiates
Phase 3 Registration Trial of TLK286 in Ovarian Cancer Patients |
|
February 28, 2003 |
Telik Announces
Presentation at Lehman Brothers Global Healthcare Conference
|
|
February 24, 2003 |
Telik Announces
Presentations at BIO CEO and Investor Conference |
|
February 13, 2003 |
Telik Announces
Fourth Quarter and Year-End 2002 Financial Results |
|
February 12, 2003 |
Telik and
Vanderbilt-Ingram Cancer Center Sign Agreement for Cancer Drug
Discovery |
|
February 7, 2003 |
Telik Announces
Quarterly Financial Release, Conference Call And Webcast |
| January
31, 2003 |
Telik to
Present at Merrill Lynch Global Pharmaceutical, Biotechnology
and Medical Device Conference |
| |
Top |
